Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 4927.19 | 578 / 578 | 100% | 37.73 | 1155 / 1155 |
stomach | 100% | 2711.27 | 359 / 359 | 100% | 37.10 | 286 / 286 |
esophagus | 100% | 3573.28 | 1444 / 1445 | 100% | 44.74 | 183 / 183 |
intestine | 100% | 3862.20 | 966 / 966 | 100% | 37.37 | 526 / 527 |
breast | 100% | 4055.47 | 459 / 459 | 100% | 42.25 | 1114 / 1118 |
prostate | 100% | 3597.74 | 245 / 245 | 99% | 32.63 | 499 / 502 |
thymus | 100% | 3483.22 | 653 / 653 | 99% | 48.26 | 599 / 605 |
bladder | 100% | 4215.10 | 21 / 21 | 99% | 33.32 | 497 / 504 |
skin | 100% | 4398.35 | 1809 / 1809 | 99% | 34.57 | 465 / 472 |
uterus | 100% | 3920.41 | 170 / 170 | 98% | 40.38 | 451 / 459 |
kidney | 100% | 2529.42 | 89 / 89 | 98% | 33.61 | 883 / 901 |
ovary | 100% | 3519.07 | 180 / 180 | 98% | 21.93 | 420 / 430 |
pancreas | 98% | 1801.13 | 323 / 328 | 99% | 37.58 | 176 / 178 |
liver | 100% | 1744.19 | 225 / 226 | 88% | 16.06 | 356 / 406 |
brain | 85% | 962.96 | 2255 / 2642 | 98% | 17.56 | 693 / 705 |
adrenal gland | 100% | 3076.69 | 258 / 258 | 83% | 11.71 | 192 / 230 |
adipose | 100% | 4639.60 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3543.21 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 68.87 | 29 / 29 |
spleen | 100% | 4477.05 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 52.12 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 12.04 | 1 / 1 |
muscle | 100% | 2304.73 | 801 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 6087.41 | 912 / 929 | 0% | 0 | 0 / 0 |
heart | 96% | 1869.42 | 828 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 90% | 15.62 | 72 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0010744 | Biological process | positive regulation of macrophage derived foam cell differentiation |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0007254 | Biological process | JNK cascade |
GO_0035994 | Biological process | response to muscle stretch |
GO_0006954 | Biological process | inflammatory response |
GO_0033554 | Biological process | cellular response to stress |
GO_0071260 | Biological process | cellular response to mechanical stimulus |
GO_0097398 | Biological process | cellular response to interleukin-17 |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_0090263 | Biological process | positive regulation of canonical Wnt signaling pathway |
GO_0045087 | Biological process | innate immune response |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_0034097 | Biological process | response to cytokine |
GO_0010956 | Biological process | negative regulation of calcidiol 1-monooxygenase activity |
GO_0071359 | Biological process | cellular response to dsRNA |
GO_0050853 | Biological process | B cell receptor signaling pathway |
GO_0032695 | Biological process | negative regulation of interleukin-12 production |
GO_0071347 | Biological process | cellular response to interleukin-1 |
GO_2000630 | Biological process | positive regulation of miRNA metabolic process |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0060056 | Biological process | mammary gland involution |
GO_0032375 | Biological process | negative regulation of cholesterol transport |
GO_0140367 | Biological process | antibacterial innate immune response |
GO_0098586 | Biological process | cellular response to virus |
GO_0051248 | Biological process | negative regulation of protein metabolic process |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_0060261 | Biological process | positive regulation of transcription initiation by RNA polymerase II |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0006915 | Biological process | apoptotic process |
GO_0071316 | Biological process | cellular response to nicotine |
GO_0038061 | Biological process | non-canonical NF-kappaB signal transduction |
GO_1900127 | Biological process | positive regulation of hyaluronan biosynthetic process |
GO_0010884 | Biological process | positive regulation of lipid storage |
GO_0010957 | Biological process | negative regulation of vitamin D biosynthetic process |
GO_0071354 | Biological process | cellular response to interleukin-6 |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_1904385 | Biological process | cellular response to angiotensin |
GO_0005576 | Cellular component | extracellular region |
GO_0035525 | Cellular component | NF-kappaB p50/p65 complex |
GO_0005739 | Cellular component | mitochondrion |
GO_0033256 | Cellular component | I-kappaB/NF-kappaB complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0034774 | Cellular component | secretory granule lumen |
GO_0005829 | Cellular component | cytosol |
GO_0035580 | Cellular component | specific granule lumen |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005667 | Cellular component | transcription regulator complex |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0003682 | Molecular function | chromatin binding |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0003712 | Molecular function | transcription coregulator activity |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0042805 | Molecular function | actinin binding |
GO_0005515 | Molecular function | protein binding |
Gene name | NFKB1 |
Protein name | Nuclear factor NF-kappa-B p105 subunit (DNA-binding factor KBF1) (EBP-1) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) [Cleaved into: Nuclear factor NF-kappa-B p50 subunit] Nuclear factor NF-kappa-B p105 subunit Nuclear factor kappa B subunit 1 Nuclear factor NF-kappa-B p105 subunit (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) |
Synonyms | |
Description | FUNCTION: NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105. .; FUNCTION: [Nuclear factor NF-kappa-B p105 subunit]: P105 is the precursor of the active p50 subunit (Nuclear factor NF-kappa-B p50 subunit) of the nuclear factor NF-kappa-B . Acts as a cytoplasmic retention of attached NF-kappa-B proteins by p105 . .; FUNCTION: [Nuclear factor NF-kappa-B p50 subunit]: Constitutes the active form, which associates with RELA/p65 to form the NF-kappa-B p65-p50 complex to form a transcription factor . Together with RELA/p65, binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions . . |
Accessions | ENST00000509165.1 A0A8V8TLB2 ENST00000394820.8 [P19838-1] P19838 ENST00000652569.1 ENST00000697794.1 ENST00000507079.6 ENST00000226574.9 [P19838-2] ENST00000652619.1 ENST00000509165.2 [P19838-2] D6RC45 A0A494C157 A0A494C1E9 D6RH30 ENST00000505458.5 [P19838-1] |